청각장애는 40개 이상의 로키가 설명되어 있는 이질적인 질환이다.이 유전자에 의해 암호화된 단백질은 태아 콜레아로 표현되지만, 그 기능은 알려져 있지 않다.비염색 청각 장애는 이 유전자의 돌연변이와 관련이 있다.[7]
DFNA5가 빈번한 유형(거스트릭, 대장, 유방)의 많은 암에서 후생적으로 비활성화된다는 관찰은 또 다른 중요한 발견이며 세포사멸 유발 성질과 일치한다.실제로 세포사멸이 DFNA5의 본질적 특징이라면 종양세포에서 유전자를 차단하면 통제되지 않는 세포성장에 더 취약해진다.더욱이 DFNA5가 P53에 의해 강력하게 규제되고 있다는 사실은 DFNA5가 종양 억제 유전자임을 시사한다.[8]
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^van Camp G, Coucke P, Balemans W, van Velzen D, van de Bilt C, van Laer L, Smith RJ, Fukushima K, Padberg GW, Frants RR (Mar 1996). "Localization of a gene for non-syndromic hearing loss (DFNA5) to chromosome 7p15". Hum Mol Genet. 4 (11): 2159–63. doi:10.1093/hmg/4.11.2159. hdl:2066/20568. PMID8589696.
^Van Laer L, Van Camp G, van Zuijlen D, Green ED, Verstreken M, Schatteman I, Van de Heyning P, Balemans W, Coucke P, Greinwald JH, Smith RJ, Huizing E, Willems P (Mar 1998). "Refined mapping of a gene for autosomal dominant progressive sensorineural hearing loss (DFNA5) to a 2-cM region, and exclusion of a candidate gene that is expressed in the cochlea". Eur J Hum Genet. 5 (6): 397–405. doi:10.1159/000484798. PMID9450185.
^de Beeck KO, Van Laer L, Van Camp G (Mar 2012). "DFNA5, a gene involved in hearing loss and cancer: a review". The Annals of Otology, Rhinology, and Laryngology. 121 (3): 197–207. doi:10.1177/000348941212100310. PMID22530481. S2CID32637216.
추가 읽기
Andersson B, Wentland MA, Ricafrente JY, Liu W, Gibbs RA (1996). "A "double adaptor" method for improved shotgun library construction". Anal. Biochem. 236 (1): 107–13. doi:10.1006/abio.1996.0138. PMID8619474.
Thompson DA, Weigel RJ (1998). "Characterization of a gene that is inversely correlated with estrogen receptor expression (ICERE-1) in breast carcinomas". Eur. J. Biochem. 252 (1): 169–77. doi:10.1046/j.1432-1327.1998.2520169.x. PMID9523727.
Van Laer L, Huizing EH, Verstreken M, van Zuijlen D, Wauters JG, Bossuyt PJ, Van de Heyning P, McGuirt WT, Smith RJ, Willems PJ, Legan PK, Richardson GP, Van Camp G (1998). "Nonsyndromic hearing impairment is associated with a mutation in DFNA5". Nat. Genet. 20 (2): 194–7. doi:10.1038/2503. PMID9771715. S2CID23534085.
Grottke C, Mantwill K, Dietel M, Schadendorf D, Lage H (2000). "Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs". Int. J. Cancer. 88 (4): 535–46. doi:10.1002/1097-0215(20001115)88:4<535::AID-IJC4>3.0.CO;2-V. PMID11058868.
Yu C, Meng X, Zhang S, Zhao G, Hu L, Kong X (2004). "A 3-nucleotide deletion in the polypyrimidine tract of intron 7 of the DFNA5 gene causes nonsyndromic hearing impairment in a Chinese family". Genomics. 82 (5): 575–9. doi:10.1016/S0888-7543(03)00175-7. PMID14559215.
Bischoff AM, Luijendijk MW, Huygen PL, van Duijnhoven G, De Leenheer EM, Oudesluijs GG, Van Laer L, Cremers FP, Cremers CW, Kremer H (2004). "A novel mutation identified in the DFNA5 gene in a Dutch family: a clinical and genetic evaluation". Audiol. Neurootol. 9 (1): 34–46. doi:10.1159/000074185. PMID14676472. S2CID20139112.
Van Laer L, Meyer NC, Malekpour M, Riazalhosseini Y, Moghannibashi M, Kahrizi K, Vandevelde A, Alasti F, Najmabadi H, Van Camp G, Smith RJ (2007). "A novel DFNA5 mutation does not cause hearing loss in an Iranian family". J. Hum. Genet. 52 (6): 549–52. doi:10.1007/s10038-007-0137-2. PMID17427029. S2CID24786210.